| Literature DB >> 6810736 |
D P Francis, S C Hadler, S E Thompson, J E Maynard, D G Ostrow, N Altman, E H Braff, P O'Malley, D Hawkins, F N Judson, K Penley, T Nylund, G Christie, F Meyers, J N Moore, A Gardner, I L Doto, J H Miller, G H Reynolds, B L Murphy, C A Schable, B T Clark, J W Curran, A G Redeker.
Abstract
A randomized, double-blind, vaccine/placebo trial of the Merck 20-micrograms hepatitis B virus (HBV) vaccine was done among 1402 homosexual men attending venereal disease clinics in five American cities. Vaccination was followed by only minimal side effects. Two doses of vaccine induced antibody in 80% of vaccine recipients. A booster dose 6 months after the first dose induced antibody in 85% of recipients and markedly increased the proportion of recipients who produced high antibody titers. The incidence of HBV events was markedly less in the vaccine recipients compared to that in the placebo recipients (p = 0.0004). Between month 3 and 15 after the first dose, 56 more significant HBV events (hepatitis, or hepatitis B surface antigen positive, or both) occurred in the placebo group while only 11 occurred in the vaccine group. Ten of the 11 HBV events in the vaccine recipients occurred in hypo- or nonresponders to the vaccine. This vaccine appears to be safe, immunogenic, and efficacious in preventing infection with hepatitis B virus.Entities:
Mesh：
Substances：
Year: 1982 PMID： 6810736 DOI： 10.7326/0003-4819-97-3-362
Source DB: PubMed Journal: Ann Intern Med ISSN： 0003-4819 Impact factor: 25.391